Company:ViiV Healthcare
 | |
| Type | Joint venture |
|---|---|
| Industry | Pharmaceutical industry |
| Founded | 2009 |
| Headquarters | London, England, UK |
Area served | Worldwide |
Key people | Deborah Waterhouse (CEO) |
| Products | Pharmaceuticals |
| Owners | |
Number of employees | c. 1,100 (2023) |
| Website | viivhealthcare |
ViiV Healthcare (/ˈviːv/ VEEV) is a British multinational pharmaceutical company specializing in the research and development of medicines to treat and prevent HIV/AIDS, with its global headquarters in London. The company was created as a joint venture by GSK and Pfizer in November 2009, with both companies transferring their HIV assets to the new company.[1] In 2012, Shionogi joined the company. As of December 2023, 76.5% of the company is owned by GSK, 13.5% by Pfizer and 10% by Shionogi.[2] According to The Financial Times, the company’s co-ownership structure may change depending on the achievement of certain milestones.[1]
ViiV Healthcare's products have a market share of approximately 32% of the global HIV therapy market, making it the second-largest healthcare company in the sector, after Gilead Sciences.[3]
ViiV Healthcare's global headquarters are in Brentford, Greater London in the United Kingdom , and the company has sites in a number of other countries including the United States, Australia, Belgium, Canada, France, Germany, Italy, Japan, Mexico, the Netherlands, Portugal, Puerto Rico, Russia, Spain and Switzerland.[4]
Products
The company markets 17 products:[5]
- Nucleoside reverse transcriptase inhibitors (NRTIs):
- abacavir (brand name Ziagen)
- lamivudine (brand names Epivir and 3TC)
- zidovudine (brand name Retrovir and AZT)
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs):
- delavirdine (brand name Rescriptor, no longer available[6])
- Attachment inhibitors
- fostemsavir (brand name Rukobia)
- Integrase strand transfer inhibitors (INSTIs):
- dolutegravir (brand name Tivicay)
- cabotegravir (brand names Apretude [as a single agent indicated for PrEP]; and Vocabria/Cabenuva [when co-administered with rilpivirine for HIV treatment - in partnership with Janssen Pharmaceuticals])
- Protease inhibitors:
- fosamprenavir (brand names Lexiva and Telzir)
- nelfinavir (brand name Viracept)
- Entry inhibitors:
- maraviroc (brand names Selzentry and Celsentri)
- Antiretroviral fixed-dose combinations, including several single-pill regimens:
- abacavir/lamivudine (brand names Epzicom and Kivexa)
- abacavir/lamivudine/zidovudine (brand name Trizivir)
- lamivudine/zidovudine (brand name Combivir)
- abacavir/dolutegravir/lamivudine (brand name Triumeq)
- dolutegravir/lamivudine (brand name Dovato)
- dolutegravir/rilpivirine (brand name Juluca - in partnership with Janssen Pharmaceuticals)
Treatment access programs
ViiV Healthcare has stated that it will continue the not-for-profit pricing schemes that Pfizer and GlaxoSmithKline had been involved in prior to the setting up of the company. This program covers all low- and middle-income countries, as well as all of Sub-Saharan Africa.[7]
The company has also granted voluntary licenses to 14 generics companies to enable the low-cost manufacture and sale of generic versions of the company's products in specific countries and/or regions.[7][8]
In March 2020, ViiV Healthcare announced the initiation of a study in partnership with University of South Carolina's Ryan White Program to determine the effectiveness of ride-sharing services in improving access to care for people living with HIV.[9]
See also
- Pharmaceutical industry in the United Kingdom
- List of pharmaceutical companies
References
- ↑ 1.0 1.1 Jacks, Andrew "GSK and Pfizer to Merge HIV Portfolios Financial Times. 16 April 2010 (Subscription content?)
- ↑ "Shionogi and ViiV Healthcare Announce New Agreement to Commercialise and Develop Integrase Inhibitor Portfolio". viivhealthcare.com. http://www.viivhealthcare.com/media/press-releases/2012/october/shionogi-and-viiv-healthcare-announce-new-agreement-to-commercialise-and-develop-integrase-inhibitor-portfolio.aspx.
- ↑ "ViiV vows joint venture will help fight HIV". https://www.ft.com/content/d4af5df8-c8ae-11de-8f9d-00144feabdc0.
- ↑ "ViiV Healthcare Company Website. About Us — Locations" Accessed 13 October 2010
- ↑ "Our HIV medicines". https://viivhealthcare.com/viiv-hiv-medicines/. Retrieved 2022-03-10.
- ↑ "Generic Rescriptor Availability". Drugs.com. https://www.drugs.com/availability/generic-rescriptor.html. Retrieved 2022-03-10.
- ↑ 7.0 7.1 "ViiV Healthcare Company Website. We Improve Access to Our Medicines" Accessed 12 January 2014
- ↑ Reuters "Glaxo, Pfizer JV Opens HIV Pipeline to Generic Companies" Africa — the Good News. 19 July 2010
- ↑ "ViiV Healthcare initiates study with the University of South Carolina to evaluate the benefits of ride-sharing services on improving access to care for people living with HIV" (in en). http://www.oleantimesherald.com/business/viiv-healthcare-initiates-study-with-the-university-of-south-carolina/article_c92c8fc3-71ba-5a82-8651-43eb62436aff.html.
 |  |
